Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 9/20 | 0.51 |
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1602484 | 0.82 | DYRK1A (0.69) | DYRK1ACDK9CA2CA12CHRNB4 | |
| SCHEMBL1602946 | 0.80 | DYRK1A (0.67) | DYRK1ACDK9CYP19A1 | |
| SCHEMBL14860130 | 0.79 | DYRK1A (0.62) | DYRK1ACDK9 | |
| SCHEMBL17165366 | 0.78 | DYRK1A (0.63) | DYRK1ACDK9KMOADORA2AADORA1 | |
| SCHEMBL28135391 | 0.78 | DYRK1A (0.65) | DYRK1ACDK9CA2CA12CHRNB4 | |
| SCHEMBL15504108 | 0.78 | DYRK1A (0.65) | DYRK1ACDK9CA2CA12CHRNB4 | |
| SCHEMBL27741085 | 0.78 | DYRK1A (0.65) | DYRK1ACDK9CA2CA12CHRNB4 | |
| SCHEMBL28275725 | 0.77 | DYRK1A (0.62) | DYRK1ACDK9CA2CA12CHRNB4 | |
| SCHEMBL21317935 | 0.75 | DYRK1A (0.58) | DYRK1ACDK9CA2CA12CHRNA7 | |
| SCHEMBL6230 | 0.74 | CYP2A6 (0.73) | DYRK1ACDK9CA2CA12CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | KYOTO UNIVERSITY (JP) | 2024-07-02 | — | — | US | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| WO-2022255411-A1 | METHOD FOR ENHANCING INNATE IMMUNE RESPONSE | 国立大学法人京都大学 | 2022-12-08 | — | — | WO | disclosed |
| EP-3508223-B1 | COMPOSITION FOR ACTIVATING NEUROGENESIS | UNIV KYOTO (JP) | 2022-05-04 | — | — | EP | disclosed |
| EP-3508223-B1 | COMPOSITION FOR ACTIVATING NEUROGENESIS | UNIV KYOTO (JP) | 2022-05-04 | — | — | EP | disclosed |
| US-11318126-B2 | Composition for activating neurogenesis | KYOTO UNIVERSITY (JP) | 2022-05-03 | — | — | US | disclosed |
| US-11318126-B2 | Composition for activating neurogenesis | KYOTO UNIVERSITY (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20210205314-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | KYOTO UNIVERSITY (JP) | 2021-07-08 | — | — | US | disclosed |
| WO-2020085319-A1 | CYCLIC AZINE COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ELECTRON TRANSPORT MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, AND ORGANIC ELECTROLUMINESCENT ELEMENT | 東ソー株式会社 | 2020-04-30 | — | — | WO | disclosed |
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | KYOTO UNIVERSITY (JP) | 2020-04-16 | — | — | US | disclosed |
| WO-2019163959-A1 | CYCLIC AZINE COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCNET ELEMENT, AND ELECTRON-TRANSPORTING MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT | 東ソー株式会社 | 2019-08-29 | — | — | WO | disclosed |
| US-20190247384-A1 | COMPOSITION FOR ACTIVATING NEUROGENESIS | KYOTO UNIVERSITY (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20190247384-A1 | COMPOSITION FOR ACTIVATING NEUROGENESIS | KYOTO UNIVERSITY (JP) | 2019-08-15 | — | — | US | disclosed |
| EP-3508223-A1 | COMPOSITION FOR ACTIVATING NEUROGENESIS | Kyoto University (JP) | 2019-07-10 | — | — | EP | disclosed |
| EP-3508223-A1 | COMPOSITION FOR ACTIVATING NEUROGENESIS | Kyoto University (JP) | 2019-07-10 | — | — | EP | disclosed |
| WO-2004058727-A1 | SUBSTITUTED 3,5-DIHYDRO-4H-IMIDAZOL-4-ONES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205314-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | RBM17, SFPQ, HNRNPAB | DYRK1A 4734/4885CDK9 3618/4885CA2 4751/4885 |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | RBM17, SFPQ, HNRNPAB | DYRK1A 4734/4885CDK9 3618/4885CA2 4751/4885 |
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | RBM17, SFPQ, HNRNPAB | DYRK1A 4734/4885CDK9 3618/4885CA2 4751/4885 |
| US-11318126-B2 | Composition for activating neurogenesis | BDNF, GAP43, DCX | DYRK1A 1021/4885CDK9 219/4885CA2 2047/4885 |
| US-20190247384-A1 | COMPOSITION FOR ACTIVATING NEUROGENESIS | BDNF, GAP43, DCX | DYRK1A 1021/4885CDK9 219/4885CA2 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.